March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Umberto Malapelle: Costs of biomarker testing in advanced non-small cell lung cancer
Mar 16, 2025, 11:09

Umberto Malapelle: Costs of biomarker testing in advanced non-small cell lung cancer

Umberto Malapelle, Associate Professor at the School of Medicine at the University of Naples Federico, shared an article on LinkedIn:

“Proud to be part of this international group of collegues!

“Widespread adoption of NGS may enable more efficient use of limited healthcare resources.”

Costs of biomarker testing in advanced non-small cell lung cancer: a global study comparing next-generation sequencing and single-gene testing.

Authors: Umberto Malapelle, et al.

Umberto Malapelle: Costs of biomarker testing in advanced non-small cell lung cancer

Svetlana Nikic, Founder of Precision Oncology Consulting, reshared the post on X, adding:

“This study, conducted across 10 pathology centers in 10 countries, compared the real-world costs of NGS and single-gene testing (SGT) for advanced NSCLC across three time-based scenarios.

Analyzing data from 4,491 patients, the study found that mean per-patient costs for NGS decreased relative to SGT over time.

In the real-world model, NGS costs were 18% lower than SGT in the ‘Starting Point’ (SP) scenario and 26% lower in the ‘Current Practice’ (CP) scenario. In the standardized model, NGS became more cost-effective than SGT when 10 biomarkers were tested in the SP scenario and 12 biomarkers in the CP scenario.

The study concluded that NGS is more cost-effective than SGT for a NSCLC biomarker testing when testing 10 or more biomarkers.

This type of studies is a key for wider adoption and reimbursement of NGS across European healthcare.

Congratulations Umberto Malapelle, Albrecht Stenzinger and many others involved!”